The Committee for Medicinal Products for Human Use (CHMP) issued an opinion supporting Mayzent (siponimod) as an oral treatment specifically for adults with active secondary progressive multiple sclerosis (SPMS) in the European Union. Opinions released by CHMP, an arm of the European Medicines Agency (EMA), carry weight and are…
Alexa
Recommended Posts
- AAN 2026: Ocrevus preserves walking, hand function in early RRMS
- My husband’s MS diagnosis changed everything — and nothing
- Enrollment complete in Phase 3 trial of at-home Briumvi injection for MS
- ‘Objective improvements’ in sleep seen with use of mindfulness in MS
- The ins, outs, ups, and downs of choosing an MS-accessible minivan